Compare Stocks: GTBP, BOLD, KVAC, and INMB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$2.80 -0.7%	$2.73	$0.96 ▼ $3.16	$64.15M	-0.03	85,225 shs	92,211 shs
GTBP GT Biopharma	$7.49 -4.1%	$7.81	$4.91 ▼ $34.25	$14.09M	0.91	105,322 shs	110,549 shs
INMB INmune Bio	$2.18 +6.3%	$2.10	$1.09 ▼ $2.60	$56.90M	0.93	338,839 shs	421,277 shs
KVAC Keen Vision Acquisition	$11.51	$11.80	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	+0.36%	-1.05%	-0.35%	+97.20%	+146.29%
GTBP GT Biopharma	-13.22%	+30.60%	+9.61%	-39.22%	-62.13%
INMB INmune Bio	-9.29%	-16.67%	-3.76%	+41.38%	+3.02%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-5.70%	-0.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$2.80 -0.7%	$2.73	$0.96 ▼ $3.16	$64.15M	-0.03	85,225 shs	92,211 shs
GTBP GT Biopharma	$7.49 -4.1%	$7.81	$4.91 ▼ $34.25	$14.09M	0.91	105,322 shs	110,549 shs
INMB INmune Bio	$2.18 +6.3%	$2.10	$1.09 ▼ $2.60	$56.90M	0.93	338,839 shs	421,277 shs
KVAC Keen Vision Acquisition	$11.51	$11.80	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	+0.36%	-1.05%	-0.35%	+97.20%	+146.29%
GTBP GT Biopharma	-13.22%	+30.60%	+9.61%	-39.22%	-62.13%
INMB INmune Bio	-9.29%	-16.67%	-3.76%	+41.38%	+3.02%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-5.70%	-0.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLD Boundless Bio	1.00	Sell	N/A	N/A
GTBP GT Biopharma	1.00	Sell	N/A	N/A
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
KVAC Keen Vision Acquisition	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest GTBP, BOLD, KVAC, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/19/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	BOLD Boundless Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	GTBP GT Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
6/23/2026	BOLD Boundless Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Reduce

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$4.41 per share	N/A
GTBP GT Biopharma	N/A	N/A	$0.36 per share	20.88	$5.66 per share	N/A
INMB INmune Bio	$50K	1,209.90	N/A	N/A	$0.88 per share	2.48
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLD Boundless Bio	-$58.20M	-$2.86	N/A	N/A	N/A	N/A	-70.89%	-47.37%	N/A
GTBP GT Biopharma	-$28.35M	-$147.50	N/A	N/A	N/A	N/A	-213.16%	-150.61%	11/13/2026 (Estimated)
INMB INmune Bio	-$45.93M	-$0.67	N/A	N/A	N/A	N/A	-82.87%	-62.23%	10/29/2026 (Estimated)
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest GTBP, BOLD, KVAC, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GTBP GT Biopharma	-$0.08	-$0.12	-$0.04	-$3.00	N/A	N/A
8/14/2026	Q2 2026	KVAC Keen Vision Acquisition	N/A	$0.08	N/A	$0.08	N/A	N/A
8/7/2026	Q2 2026	BOLD Boundless Bio	N/A	-$1.06	N/A	-$1.06	N/A	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLD Boundless Bio	N/A	9.48	9.48
GTBP GT Biopharma	N/A	2.61	2.61
INMB INmune Bio	N/A	4.04	4.04
KVAC Keen Vision Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLD Boundless Bio	N/A
GTBP GT Biopharma	8.15%
INMB INmune Bio	12.72%
KVAC Keen Vision Acquisition	51.72%

Insider Ownership

Company	Insider Ownership
BOLD Boundless Bio	23.10%
GTBP GT Biopharma	1.18%
INMB INmune Bio	21.40%
KVAC Keen Vision Acquisition	80.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLD Boundless Bio	28	22.75 million	17.49 million	No Data
GTBP GT Biopharma	8	1.80 million	1.78 million	No Data
INMB INmune Bio	21	27.75 million	21.82 million	Optionable
KVAC Keen Vision Acquisition	N/A	5.51 million	1.09 million	Not Optionable

GTBP, BOLD, KVAC, and INMB Headlines

Recent News About These Companies

Keen Vision Extends Timeline for Business Combination Deal

July 28, 2026 | tipranks.com

Keen Vision Acquisition Extends SPAC Deadline with Sponsor Note

April 27, 2026 | tipranks.com

Keen Vision, Medera Extend Timeline for Revised Merger

April 15, 2026 | tipranks.com

Keen Vision Signs New Letter of Intent with Novoheart

March 2, 2026 | tipranks.com

Keen Vision Extends SPAC Timeline and Secures Funding

January 26, 2026 | tipranks.com

Keen Vision Acquisition Extends Business Combination Deadline

January 5, 2026 | tipranks.com

Keen Vision Issues Promissory Note for Business Extension

November 24, 2025 | tipranks.com

Keen Vision Acquisition (NASDAQ:KVAC) Trading 0.5% Higher â€“ Still a Buy?

November 22, 2025 | defenseworld.netD

Keen Vision Extends Business Combination Deadline

September 25, 2025 | tipranks.com

Keen Vision Transfers Funds to Trust Account

September 2, 2025 | tipranks.com

Keen Vision Issues Promissory Note to Extend Merger Time

August 22, 2025 | tipranks.com

KVAC Keen Vision Acquisition Corporation - Seeking Alpha

June 29, 2025 | seekingalpha.com

Keen Vision Issues Promissory Note to Extend Deadline

June 27, 2025 | tipranks.com

Keen Vision Acquisition Corporation (KVACW) - Yahoo Finance

June 27, 2025 | au.finance.yahoo.com

Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025

June 13, 2025 | globenewswire.com

Keen Vision Acquisition Corporation Ordinary Shares

June 6, 2025 | fxempire.comF

Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress

May 12, 2025 | globenewswire.com

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

April 1, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/04/01/3053271/0/en/medera-presented-updated-results-from-first-in-human-gene-therapy-trial-for-heart-failure-with-preserved-ejection-fraction-at-2025-hfpef-summit.html$

Keen Vision Acquisition Corp. Secures Funding to Extend Merger Deadline

March 30, 2025 | investing.com

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

March 20, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/03/20/3046150/0/en/medera-receives-dsmb-clearance-to-initiate-phase-2-portion-of-music-hfref-phase-1b-2-trial-for-srd-001-gene-therapy-in-heart-failure-with-reduced-ejection-fraction.html$

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GTBP, BOLD, KVAC, and INMB Company Descriptions

Boundless Bio NASDAQ:BOLD

$2.80 -0.02 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$2.79 -0.01 (-0.36%)

As of 07:30 PM Eastern

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

GT Biopharma NASDAQ:GTBP

$7.49 -0.32 (-4.10%)

Closing price 04:00 PM Eastern

Extended Trading

$7.49 0.00 (0.00%)

As of 07:55 PM Eastern

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

INmune Bio NASDAQ:INMB

$2.18 +0.13 (+6.34%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 +0.00 (+0.23%)

As of 07:44 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)

As of 09/16/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GTBP, BOLD, KVAC, and INMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GTBP, BOLD, KVAC, and INMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GTBP, BOLD, KVAC, and INMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GTBP, BOLD, KVAC, and INMB Company Descriptions

Boundless Bio NASDAQ:BOLD

GT Biopharma NASDAQ:GTBP

INmune Bio NASDAQ:INMB

Keen Vision Acquisition NASDAQ:KVAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GTBP, BOLD, KVAC, and INMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GTBP, BOLD, KVAC, and INMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GTBP, BOLD, KVAC, and INMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GTBP, BOLD, KVAC, and INMB Company Descriptions

Boundless Bio NASDAQ:BOLD

GT Biopharma NASDAQ:GTBP

INmune Bio NASDAQ:INMB

Keen Vision Acquisition NASDAQ:KVAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools